CAS 220673-95-0

Antisauvagine-30

Description:

Antisauvagine-30 is a synthetic peptide that serves as a selective antagonist for the corticotropin-releasing factor (CRF) receptor, specifically targeting the CRF1 receptor subtype. This peptide is derived from the structure of sauvagine, a naturally occurring peptide found in the skin of certain amphibians. Antisauvagine-30 is characterized by its ability to inhibit the actions of CRF, which plays a crucial role in the stress response and various physiological processes, including anxiety and depression. The molecular structure of Antisauvagine-30 consists of a sequence of amino acids that confer its biological activity and specificity. It is often used in research to study the role of CRF in stress-related disorders and to explore potential therapeutic applications. Additionally, its relatively small size and specific receptor binding properties make it a valuable tool in pharmacological studies. As with many peptides, stability and delivery methods are important considerations in its application in both research and potential clinical settings.

(D-Phe¹¹,His¹²)-Sauvagine (11-40)

CAS: 220673-95-0

ASV-30, a conformationally constrained analog of sauvagine, is a highly potent and selective antagonist directed against mouse CRF receptor type 2β (mCRFR2β). It has been shown to suppress agonist-induced adenylate cyclase activity in human embryonic kidney (HEK) 293 cells expressing mCRFR2β.

Formula: C₁₆₁H₂₇₄N₄₈O₄₆S

Purity: > 95%

Color and Shape: White Lyophilisate

Molecular weight: 3650.31

Ref: 01-4034828

Antisauvagine-30

CAS: 220673-95-0

CRF2 receptor antagonist; Kd 1.4 nM (mCRF2β), 153.6 nM (rCRF1). Blocks sauvagine-induced cAMP in cells & stress-related responses in mice.

Formula: C₁₆₁H₂₇₄N₄₈O₄₆S

Purity: 98%

Color and Shape: Solid

Molecular weight: 3650.29

Ref: TM-TP2091

(D-Phe11,His12)-Sauvagine (11-40) trifluoroacetate salt

CAS: 220673-95-0

This is a synthetic peptide analog of Sauvagine (11-40) that is an inhibitor of myosin phosphatase. It has been shown to have locomotor activity and physiological effects in rat models. The peptide binds to the ryanodine receptor and inhibits the release of cytosolic calcium, which leads to the transcription-polymerase chain reaction. Chronic exposure has been shown to cause brain dysfunction, including symptoms such as hypoactivity and hyperactivity, with receptor knockout leading to neuronal death. This discovery may lead to a pharmacological treatment for epilepsy.

Formula: C₁₆₁H₂₇₄N₄₈O₄₆S

Purity: Min. 95%

Molecular weight: 3,650.26 g/mol

Ref: 3D-FP109630